AlphaMeld
Partnerships

Multi-year collaborations with global pharma.

Selected partner engagements span target discovery, indication expansion, repurposing, and clinical development. Specific outcome figures are illustrative; actual milestones are governed by individual partnership agreements.

Kyowa KirinTakedaAlexionShionogiOno PharmaNektarBioXcelCentrexionTB AllianceMueller Health FoundationKyowa KirinTakedaAlexionShionogiOno PharmaNektarBioXcelCentrexionTB AllianceMueller Health Foundation
Kyowa Kirin

Kyowa Kirin

2018–presentMulti-year strategic collaboration

Enterprise-wide platform access. Multiple expansions of scope across therapeutic areas and modalities; first research-collaboration milestone achieved.

Shionogi

Shionogi

2021–presentMulti-target drug discovery

Joint identification, evaluation, and optimization of novel targets; Shionogi advances selected programs into research and clinical development.

Ono Pharmaceutical

Ono Pharmaceutical

2024–presentTarget identification across diseases of interest

Ono leverages AlphaMeld and ChatAlphaMeld to identify, evaluate, and optimize novel targets, with exclusive global commercialization rights to advancing candidates.

GSK Consumer Healthcare

GSK Consumer Healthcare

2020–presentInnovation monitoring across consumer health

Three-year strategic collaboration applying AlphaMeld to capture consumer-specific innovation across GSK's key focus areas.

Sosei Heptares

Sosei Heptares

2021–presentGPCR-focused target discovery

Combined AlphaMeld with Sosei Heptares' GPCR structure-based drug design to surface and validate undrugged GPCR targets in immunomodulation.

TB Alliance

TB Alliance

2020–presentDrug-resistant tuberculosis

Application of AlphaMeld to identify and accelerate transformative therapies for the management, treatment, and cure of tuberculosis.

Nektar Therapeutics

Nektar Therapeutics

CollaborationCytokine engineering & immuno-oncology

Strategic engagement with Nektar's R&D leadership informing AlphaMeld's translational approach to biologics innovation.

Centrexion

Centrexion

CollaborationNon-opioid pain

Application of AlphaMeld in the pain therapeutic space, supporting target landscape work and program prioritization.

BioXcel Therapeutics

BioXcel Therapeutics

SpinoutSister-company spinout

Validated AlphaMeld outputs across BioXcel programs, including BXCL501 — among the first AI-platform-derived candidates to complete a successful Phase III readout.

Get started

Ready to compress your discovery timelines?

See AlphaMeld run a live target-discovery workflow on your therapy area in 30 minutes.